<mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" version="3.3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>RECURRENCE OF CHCV AFTER THE USE OF DIRECT ANTIVIRAL  DRUGS: CLINICS, DIAGNOSIS, TREATMENT AND OUTCOMES</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Jurayev J.S.,</mods:namePart><mods:namePart type="family">Jurayev J.S.,</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Karshiev.M.A</mods:namePart><mods:namePart type="family">Karshiev.M.A</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Uralov A.A</mods:namePart><mods:namePart type="family">Uralov A.A</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Viral hepatitis C is one of the leading liver diseases. According to WHO, 70 million people are infected with this disease. HCV kills 290,000 people every year. In 95% of patients, the disease becomes chronic, and the main complications are fibrosis and cirrhosis of the liver. In some cases, a relapse is observed, despite treatment with antiviral drugs.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-05-12</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>